Figures computed from official regulatory filings — .
Ownershipinsiders 38.23% · institutions 8.1% · short 3.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Rafael Holdings, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys6 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Polinsky David | Other | $4.1K | SEC |
| JONAS HOWARD Strack record | Award | $150K | SEC |
| Polinsky David | Other | $6.3K | SEC |
| JONAS HOWARD Strack record | Other | $20.5K | SEC |
| JONAS HOWARD Strack record | Award | $250K | SEC |
| Polinsky David | Other | $3K | SEC |
| JONAS HOWARD Strack record | Other | $14.7K | SEC |
| Sieger Markus | Award | $37.5K | SEC |
| GRAYSON ALAN | Award | $8.3K | SEC |
| WEISS MICHAEL J | Award | $50K | SEC |
| STEIN MARK N | Award | $50K | SEC |
| Polinsky David | Award | $62.5K | SEC |
| Polinsky David | Other | $6.1K | SEC |
| JONAS HOWARD Strack record | Award | $93.8K | SEC |
| Polinsky David | Other | $2.5K | SEC |
| JONAS HOWARD Strack record | Other | $14.8K | SEC |
| Polinsky David | Other | $5.6K | SEC |
| Polinsky David | Other | $1.9K | SEC |
| Polinsky David | Other | $2.9K | SEC |
| JONAS HOWARD Strack record | Other | $13.4K | SEC |
| Fine Joshua M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Polinsky David | Other | $3.8K | SEC |
| JONAS HOWARD Strack record | Award | $250.2K | SEC |
| JONAS HOWARD Strack record | Buy | $415K | conv 43First in 12mo | SEC |
| JONAS HOWARD Strack record | Buy | $15.7M | conv 74Unusual sizeFirst in 12mo | SEC |